Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial
暂无分享，去创建一个
A. Hauschild | D. Schadendorf | K. Flaherty | P. Ascierto | R. Dummer | J. Larkin | J. Sosman | J. Kirkwood | A. Ribas | A. Eggermont | A. Testori | C. Garbe | A. Joe | T. Jouary | P. Chapman | G. McArthur | J. Haanen | D. Hogg | P. Lorigan | C. Lebbé | S. O’Day | B. Dréno | K. Nolop | B. Nelson | Richard J Lee | C. Robert | Jiang Li | Maio Michele | S. O'Day